Aerie Pharmaceuticals confirmed the effect of Rhopressa on trabecular meshwork outflow in patients with open-angle glaucoma or ocular hypertension, according to the topline results of a double-masked, randomized, placebo-controlled study designed to evaluate the eye drop’s mechanism of action.
The study enrolled patients diagnosed with open-angle glaucoma or ocular hypertension in both eyes who had unmedicated baseline IOP between 20 mm Hg and 30 mm Hg. The study evaluated the effect of Rhopressa (netarsudil ophthalmic solution 0.02%) on aqueous humor dynamics, according to a company
Uncategorized